Inventor · disambiguated record
Ling Li
Also filed as: LI LING · LI LING-WEI
82 granted patents·38 pending applications·182 citations·filing 1995–2024
98Inventor score
Top patents by PatentIndex Score
120 records- 0195US10941129B2Benzyl phenyl ether derivative, preparation method therefor, and pharmaceutical composition and uses thereofINST MATERIA MEDICA CAMS·Filed 2017·Granted Mar 9, 2021·13 cites·24 claims
- 0295US10882833B2Phenylate derivative, preparation method therefor, and pharmaceutical composition and uses thereofINST MATERIA MEDICA CAMS·Filed 2017·Granted Jan 5, 2021·13 cites·22 claims
- 0394US10975049B2Nicotinyl alcohol ether derivative, preparation method therefor, and pharmaceutical composition and uses thereofINST MATERIA MEDICA CAMS·Filed 2017·Granted Apr 13, 2021·13 cites·16 claims
- 0493US11207325B2Triazolopyrimidine compounds and uses thereofNOVARTIS AG·Filed 2020·Granted Dec 28, 2021·3 cites·19 claims
- 0589US9580437B2Triazolopyrimidine compounds and uses thereofCHAN HO MAN·Filed 2015·Granted Feb 28, 2017·15 cites·20 claims
- 0687US10450347B2ImmunomodulatorsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Oct 22, 2019·6 cites·23 claims
- 0787US10358463B2ImmunomodulatorsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jul 23, 2019·7 cites·15 claims
- 0886US9090889B2Xylose isomerases and their usesNUNN JR DAVID NEAL·Filed 2013·Granted Jul 28, 2015·11 cites·39 claims
- 0984USRE46873EMulti-targeted RNAi therapeutics for scarless wound healing of skinSIRNAOMICS INC·Filed 2008·Granted May 29, 2018·5 cites·21 claims
- 1083US8987471B2Substituted dihydropyrazoles as sphingosine receptor modulatorsALLERGAN INC·Filed 2014·Granted Mar 24, 2015·6 cites·9 claims
- 1183US8735567B2Multi-targeted RNAi therapeutics for scarless wound healing of skinLU PATRICK Y·Filed 2008·Granted May 27, 2014·5 cites·12 claims
- 1283US7648967B2Mutagenic nucleoside analogs for the treatment of viral diseaseKORONIS PHARMACEUTICALS INC·Filed 2006·Granted Jan 19, 2010·2 cites·6 claims
- 1382US12037594B2Modification of transcriptional repressor binding site in NF-YC4 promoter for increased protein content and resistance to stressUNIV IOWA STATE RES FOUND INC·Filed 2022·Granted Jul 16, 2024·0 cites·11 claims
- 1482US11492375B2Cyclic peptide immunomodulatorsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Nov 8, 2022·2 cites·16 claims
- 1581US10689378B2Triazolopyridine compounds and uses thereofNOVARTIS AG·Filed 2017·Granted Jun 23, 2020·4 cites·18 claims
- 1681US10220036B2Triazolopyrimidine compounds and uses thereofNOVARTIS AG·Filed 2015·Granted Mar 5, 2019·3 cites·26 claims
- 1781US7226951B2Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the sameALLERGAN INC·Filed 2004·Granted Jun 5, 2007·13 cites·4 claims
- 1879US10676479B2Imidazolepyridine compounds and uses thereofNOVARTIS AG·Filed 2017·Granted Jun 9, 2020·2 cites·10 claims
- 1979US8541396B2Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agentMOORE PHILIP KEITH·Filed 2009·Granted Sep 24, 2013·6 cites·2 claims
- 2078US8273776B2Biphenyl oxadiazole derivatives as sphingosine-1-phosphate receptors modulatorsTAKEUCHI JANET A·Filed 2011·Granted Sep 25, 2012·4 cites·4 claims
- 2176US10640781B2Modification of transcriptional repressor binding site in NF-YC4 promoter for increased protein content and resistance to stressUNIV IOWA STATE RES FOUND INC·Filed 2016·Granted May 5, 2020·1 cites·12 claims
- 2276US2024400501A13,4-disubstituted 3-cyclobutene-1,2-diones and use thereofALLERGAN INC·Filed 2024·Application pending·0 cites
- 2375US11931363B2Triazolopyrimidine compounds and uses thereofNOVARTIS AG·Filed 2021·Granted Mar 19, 2024·0 cites·22 claims
- 2475US9833497B2Human originated EGF domain proteins and use of the sameCHENGDU SOURCEBIO LIMITED-LIABILITY COMPANY·Filed 2014·Granted Dec 5, 2017·4 cites·18 claims
- 2574US10493165B2Extracellular vesicles for agent deliveryUNIV JOHNS HOPKINS·Filed 2016·Granted Dec 3, 2019·1 cites·28 claims
- 2674US2022402866A13,4-disubstituted 3-cyclobutene-1,2-diones and use thereofALLERGAN INC·Filed 2021·Application pending·0 cites
- 2773US8080570B2α2B and α2C agonistsTAKEUCHI JANET A·Filed 2009·Granted Dec 20, 2011·1 cites·2 claims
- 2872US8729110B12-thio-1,3,4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulatorsALLERGAN INC·Filed 2013·Granted May 20, 2014·1 cites·10 claims
- 2971US11208377B23,4-disubstituted 3-cyclobutene-1,2-diones and use thereofALLERGAN INC·Filed 2018·Granted Dec 28, 2021·0 cites·6 claims
- 3071US7468391B2Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26BALLERGAN INC·Filed 2004·Granted Dec 23, 2008·5 cites·12 claims
- 3170US11542520B2Modification of transcriptional repressor binding site in NF-YC4 promoter for increased protein content and resistance to stressUNIV IOWA STATE RES FOUND INC·Filed 2020·Granted Jan 3, 2023·0 cites·17 claims
- 3270US8658623B2Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulatorsALLERGAN INC·Filed 2013·Granted Feb 25, 2014·1 cites·8 claims
- 3370US8513418B2Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulatorsTAKEUCHI JANET A·Filed 2012·Granted Aug 20, 2013·1 cites·10 claims
- 3470US8440698B23-(4-((1H-imidazol-1-yl)methyl)phenyl)-5-aryl-1,2,4-oxadiazole derivatives as sphingosine-1 phosphate receptors modulatorsTAKEUCHI JANET A·Filed 2012·Granted May 14, 2013·1 cites·8 claims
- 3569US8729109B23-(4-(5-phenyl-1 ,2,4-oxadiazol-3-yl)phenoxy)propan-2-ol derivatives as sphingosine-1phosphate receptors modulatorsTAKEUCHI JANET A·Filed 2012·Granted May 20, 2014·1 cites·11 claims
- 3668US8497255B2Phosphonic acids as S1P receptor modulatorsTAKEUCHI JANET A·Filed 2011·Granted Jul 30, 2013·1 cites·10 claims
- 3765US7244717B2Mutagenic nucleoside analogs for the treatment of viral diseaseKORONIS PHARMACEUTICALS INC·Filed 2002·Granted Jul 17, 2007·2 cites·6 claims
- 3865US2024216378A1Triazolopyrimidine compounds and uses thereofNOVARTIS AG·Filed 2024·Application pending·0 cites
- 3965US2020197535A1Extracellular vesicles for agent deliveryUNIV JOHNS HOPKINS·Filed 2019·Application pending·0 cites
- 4064US8846729B22-thio-1,3,4-oxadiazoles azetidine derivatives as sphingosine-1 phosphate receptors modulatorsALLERGAN INC·Filed 2013·Granted Sep 30, 2014·0 cites·5 claims
- 4164US2020018743A1Mini-cancers utilization for personalized cancer drug regimensUNIV JOHNS HOPKINS·Filed 2019·Application pending·0 cites
- 4264US2010111908A1Induction of Renal Cells for Treatment of Kidney DiseaseLIN FANGMING·Filed 2009·Application pending·0 cites
- 4363US8946195B2Bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulatorsALLERGAN INC·Filed 2014·Granted Feb 3, 2015·0 cites·8 claims
- 4463US8735399B2Selective subtype alpha 2 adrenergic agents and methods for use thereofHEIDELBAUGH TODD M·Filed 2009·Granted May 27, 2014·0 cites·11 claims
- 4562US10626407B2Materials and method for modifying a biochemical component in a plantUNIV IOWA STATE RES FOUND INC·Filed 2017·Granted Apr 21, 2020·0 cites·6 claims
- 4662US2025387371A1Compositions and formulation methods for sustained local release of antifibroticsTHE HOPKINS UNIVERISTY·Filed 2023·Application pending·0 cites
- 4762US2019142837A1Triazolopyrimidine compounds and uses thereofNOVARTIS AG·Filed 2019·Application pending·0 cites
- 4860US9850494B2Materials and method for modifying a biochemical component in a plantUNIV IOWA STATE RES FOUND INC·Filed 2015·Granted Dec 26, 2017·0 cites·20 claims
- 4960US8865684B2Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agentUNIV SINGAPORE·Filed 2013·Granted Oct 21, 2014·0 cites·1 claims
- 5060US8653050B2Phenyl bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulatorsALLERGAN INC·Filed 2013·Granted Feb 18, 2014·0 cites·10 claims
Showing the top 50 of 120 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Ling Li files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →